Terms: = Lymphoma AND STIL, SIL, 6491, ENSG00000123473, Q15468 AND Clinical Outcome
19 results:
1. Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study.
Choi I; Okada M; Ito T
Ann Hematol; 2023 May; 102(5):1149-1158. PubMed ID: 36995403
[TBL] [Abstract] [Full Text] [Related]
2. CARMA1 is required for Notch1-induced NF-κB activation in sil-TAL1-negative T cell acute lymphoblastic leukemia.
Zhang N; Xu J; Wang R; Pan T; Zhang H; Yin L; Yao Y; Xu L; Zhu S; Wu Q; Li Z; Liu X; Xu K; Niu M
J Mol Med (Berl); 2021 Oct; 99(10):1447-1458. PubMed ID: 34223928
[TBL] [Abstract] [Full Text] [Related]
3. Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy.
Umino K; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2019 Sep; 98(9):2121-2129. PubMed ID: 31240469
[TBL] [Abstract] [Full Text] [Related]
4. Impact of the soluble interleukin-2 receptor level in the relapsed or refractory phase on the clinical outcome of patients with diffuse large B-cell lymphoma.
Umino K; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Leuk Lymphoma; 2019 Aug; 60(8):1926-1933. PubMed ID: 30947577
[TBL] [Abstract] [Full Text] [Related]
5. Low level of serum HDL-cholesterol with increased sil-2R predicts a poor clinical outcome for patients with malignant lymphoma and adult T-cell leukemia-lymphoma.
Komiya I; Tomoyose T; Ouchi G; Yara T; Higa S
Cytokine; 2018 May; 105():57-62. PubMed ID: 29459344
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
[TBL] [Abstract] [Full Text] [Related]
7. Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma.
Gupta M; Stenson M; O'Byrne M; Maurer MJ; Habermann T; Cerhan JR; Weiner GW; Witzig TE
Ann Oncol; 2016 Jan; 27(1):165-72. PubMed ID: 26487586
[TBL] [Abstract] [Full Text] [Related]
8. Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma.
Sonbol MB; Maurer MJ; Stenson MJ; Allmer C; LaPlant BR; Weiner GJ; Macon WR; Cerhan JR; Witzig TE; Gupta M
Am J Hematol; 2014 Dec; 89(12):E223-7. PubMed ID: 25164110
[TBL] [Abstract] [Full Text] [Related]
9. NKX2-5, sil/TAL and TLX3/HOX11L2 expression in Egyptian pediatric T-cell acute lymphoblastic leukemia.
Moussa H; Sidhom I
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e1-10. PubMed ID: 24571118
[TBL] [Abstract] [Full Text] [Related]
10. Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma.
Heemann C; Kreuz M; Stoller I; Schoof N; von Bonin F; Ziepert M; Löffler M; Jung W; Pfreundschuh M; Trümper L; Kube D
Clin Cancer Res; 2012 Jul; 18(13):3637-47. PubMed ID: 22573350
[TBL] [Abstract] [Full Text] [Related]
11. Serum soluble interleukin-2 receptor (sil-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
[TBL] [Abstract] [Full Text] [Related]
12. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract] [Full Text] [Related]
13. Serological immunomarkers in cutaneous T cell lymphoma.
Hassel JC; Meier R; Joller-Jemelka H; Burg G; Dummer R
Dermatology; 2004; 209(4):296-300. PubMed ID: 15539892
[TBL] [Abstract] [Full Text] [Related]
14. Serum-soluble interleukin-2 receptor (sil-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
[TBL] [Abstract] [Full Text] [Related]
15. clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of sil-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951.
Cavé H; Suciu S; Preudhomme C; Poppe B; Robert A; Uyttebroeck A; Malet M; Boutard P; Benoit Y; Mauvieux L; Lutz P; Méchinaud F; Grardel N; Mazingue F; Dupont M; Margueritte G; Pages MP; Bertrand Y; Plouvier E; Brunie G; Bastard C; Plantaz D; Vande Velde I; Hagemeijer A; Speleman F; Lessard M; Otten J; Vilmer E; Dastugue N;
Blood; 2004 Jan; 103(2):442-50. PubMed ID: 14504110
[TBL] [Abstract] [Full Text] [Related]
16. A multiplex reverse transcriptase-polymerase chain reaction strategy for the diagnostic molecular screening of chimeric genes: a clinical evaluation on 170 patients with acute lymphoblastic leukemia.
Elia L; Mancini M; Moleti L; Meloni G; Buffolino S; Krampera M; De Rossi G; Foà R; Cimino G
Haematologica; 2003 Mar; 88(3):275-9. PubMed ID: 12651265
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan.
Kono N; Kanda Y; Yamamoto R; Chizuka A; Suguro M; Hamaki T; Arai C; Matsuyama T; Takezako N; Miwa A; Togawa A
Leuk Lymphoma; 2000 Mar; 37(1-2):151-6. PubMed ID: 10721779
[TBL] [Abstract] [Full Text] [Related]
18. Serum levels of interleukin-2 receptor (CD 25) in patients with Hodgkin's disease, with special reference to age and prognosis.
Enblad G; Sundström C; Gronowitz S; Glimelius B
Ann Oncol; 1995 Jan; 6(1):65-70. PubMed ID: 7710984
[TBL] [Abstract] [Full Text] [Related]
19. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
[TBL] [Abstract] [Full Text] [Related]
